Archive

Neovasc’s Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

NASDAQ, TSX: NVCN VANCOUVER, May 15, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its management and board of directors (the "Board") urge the Company's shareholders...

Read More

Neovasc Announces Results for the First Quarter 2018

NASDAQ, TSX: NVCN VANCOUVER, May 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced financial results for the quarter ended March 31, 2018 (all figures in U.S....

Read More

Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

NASDAQ, TSX: NVCN VANCOUVER, May 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has received written notification (the "Nasdaq Notice") from The Nasdaq Stock...

Read More

Neovasc Provides a General Update, Announces Filing of Annual Report on Form 20-F and Sets First Quarter 2018 Financial Results Conference Call and Webcast

NASDAQ, TSX: NVCN VANCOUVER, April 30, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided a general corporate update, concurrent with filing its Annual Report on Form 20-F,...

Read More

Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants

NASDAQ, TSX: NVCN VANCOUVER, April 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and the Neovasc Reducer™ (the "Reducer") therapy for Refractory Angina, today announced that it has...

Read More

Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2017

NASDAQ, TSX: NVCN VANCOUVER, March 28, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and the Reducer therapy for Refractory Angina, today announced financial results for the fourth quarter...

Read More